Evidence map›Paper›PMID 26700954›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2016

Functional Comparison of Human Colonic Carcinoma Cell Lines and Primary Small Intestinal Epithelial Cells for Investigations of Intestinal Drug Permeability and First-Pass Metabolism.

Yoshiyuki Yamaura, Brian D Chapron, Zhican Wang, Jonathan Himmelfarb, Kenneth E Thummel

Open access · bronzeAbstract read
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 52 citations in OpenAlex.

  1. Glycoprotein Mucin 13 Expression as a Theranostic Target in Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Evaluation of Caco-2 and human intestinal epithelial cells asBiochemistry and biophysics reports · 2022
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yoshiyuki YamauraDepartment of Pharmaceutics (Y.Y., B.D.C., Z.W., K.E.T.) and Nephrology (J.H.), University of Washington, Seattle, Washington.
Brian D ChapronDepartment of Pharmaceutics (Y.Y., B.D.C., Z.W., K.E.T.) and Nephrology (J.H.), University of Washington, Seattle, Washington.
Zhican WangDepartment of Pharmaceutics (Y.Y., B.D.C., Z.W., K.E.T.) and Nephrology (J.H.), University of Washington, Seattle, Washington.
Jonathan HimmelfarbDepartment of Pharmaceutics (Y.Y., B.D.C., Z.W., K.E.T.) and Nephrology (J.H.), University of Washington, Seattle, Washington.
Kenneth E ThummelDepartment of Pharmaceutics (Y.Y., B.D.C., Z.W., K.E.T.) and Nephrology (J.H.), University of Washington, Seattle, Washington thummel@u.washington.edu.
University of Washington · US

Funding

NRSA Training CoreTL1TR002318 · NCATS · UNIVERSITY OF WASHINGTON · PI Megan Moore · 2017 to 2026
$8.4M
Using iPSCs to model patient outcomes in nephrotic syndromeUH3TR000504 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2014 to 2016
$6.1M
Hormonal Regulation of Human CYP3AR01GM063666 · NIGMS · UNIVERSITY OF WASHINGTON · PI THUMMEL, KENNETH E. · 2002 to 2017
$5.3M
Institute of Translational Health SciencesTL1TR000422 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$2.1M
A Tissue Engineered Human Kidney Microphysiological SystemUH2TR000504 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2012 to 2013
$2.1M
NCATS NIH HHS TL1 TR000422NCATS NIH HHS TL1TR000422NCATS NIH HHS TL1 TR002318NCATS NIH HHS UH2 TR000504NCATS NIH HHS UH3 TR000504NIGMS NIH HHS R01 GM063666
6 · The paper itself

Abstract

To further the development of a model for simultaneously assessing intestinal absorption and first-pass metabolism in vitro, Caco-2, LS180, T84, and fetal human small intestinal epithelial cells (fSIECs) were cultured on permeable inserts, and the integrity of cell monolayers, CYP3A4 activity, and the inducibility of enzymes and transporters involved in intestinal drug disposition were measured. Caco-2, T84, and fSIECs all formed tight junctions, as assessed by immunofluorescence microscopy for zonula occludens-1, which was well organized into circumscribing strands in T84, Caco-2, and fSIECs but was diffuse in LS180 cells. The transepithelial electrical resistance value for LS180 monolayers was lower than that for Caco-2, T84, and fSIECs. In addition, the apical-to-basolateral permeability of the paracellular marker Lucifer yellow across LS180 monolayers was greater than in fSIECs, T84, and Caco-2 monolayers. The transcellular marker propranolol exhibited similar permeability across all cells. With regard to metabolic capacity, T84 and LS180 cells showed comparable basal midazolam hydroxylation activity and was inducible by rifampin and 1α,25(OH)2D3 in LS180 cells, but only marginally so in T84 cells. The basal CYP3A4 activity of fSIECs and Caco-2 cells was much lower and not inducible. Interestingly, some of the drug transporters expressed in LS180 and Caco-2 cells were induced by either 1α,25(OH)2D3 or rifampin or both, but effects were limited in the other two cell lines. These results suggest that none of the cell lines tested fully replicated the drug disposition properties of the small intestine and that the search for an ideal screening tool must continue.

Indexed as

Biological TransportCaco-2 CellsCalcitriolCarcinomaCell Line, TumorCell Membrane PermeabilityColonic NeoplasmsCytochrome P-450 CYP3AEpithelial CellsHumansIntestinal AbsorptionIntestine, SmallPharmaceutical PreparationsRifampinCalcitriolCytochrome P-450 CYP3APharmaceutical PreparationsRifampin

Identifiers

PMID26700954
PMCPMC4767385
OpenAlexW2271612480

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.